Abstract 22P
Background
DNA damage response (DDR) pathways are essential to sustain genomic stability and play a critical role in cancer development and progression. Here, we investigated DDR genes mutations profile in early-stage non-small cell lung cancer (NSCLC) and their prognostic values.
Methods
We first examined 74 DDR genes involved in seven DDR pathways and then focused on six specific genes: ATM, BRCA1/2, CHEK1, BARD1, BRIP1. A total of 179 stage I and IIIa NSCLC patients who received curative resection in Peking Union Medical College Hospital and their corresponding samples were collected for DNA sequencing, immunohistochemistry and survival analysis.
Results
A total of 167 eligible patients were finally analyzed. Mutation frequencies were 82% and 26.3% for the selected 74 genes and 6 genes, respectively. No association was found between DDR gene status and PD-L1 expression, CD8 positive lymphocyte and tumor-associated macrophage (TAM) infiltration in tumor area. Numbers of gene mutations was significantly increased among patients with DDR alterations. Deleterious mutations in ATM, BRCA1/2, CHEK1, BARD1 and BRIP1 were independent prognostic indicators of significantly longer disease-free survival.
Conclusions
Deleterious mutations of these six genes were common in early-stage NSCLC and may serve as prognostic biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
National High Level Hospital Clinical Research Funding (to MW), Grant/Award Number:2022-PUMCH-B-106.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09